Date and TimeTitle
Apr 27, 2021
10:00am - 10:45am (Eastern)
Keynote - Leveraging Data from Clinical Trial Participants to Nation-scale Cohorts

Within Pharma, large genomic groups and a few big health systems large collections of patients/participants have hundreds of millions of data sets from real world data (insurance claims and electronic health records), population scale cohorts with whole genome sequencing or imputed whole genome and in some cases all these data on the same individuals. These data sets combined with computational biologists and large compute farms are identifying many variants of potential interest related to new targets, better disease definition, better understanding of disease mechanism, patient stratification and ultimately patient care.

Apr 27, 2021
10:50am - 11:50am (Eastern)
Comprehensive Genomic Profiling: A New Standard of Care in Oncology
  • The landscape for comprehensive genomic profiling
  • The obstacles to coverage & reimbursement
  • Access to Comprehensive Genomic Profiling Coalition
Apr 27, 2021
11:55am - 12:45pm (Eastern)
Factors Influencing Health Plans in Covering A New Diagnostic Technology
Apr 27, 2021
12:50pm - 1:35pm (Eastern)
Keynote - The Path to Preventive Genomics

It is now 20 years since the completion of the first draft of the Human Genome Project. While there have been enormous breakthroughs in diagnostics and biotechnology, the promise of using genomics to stratify risk and prevent human disease has not been realized. This presentation will summarize recent data from the MedSeq and BabySeq Projects which are the first randomized trials to assess medical, behavioral and economic impact of comprehensive sequencing in healthy adults and newborn infants, respectively. This presentation will also describe a new vision for clinical utility research in preventive genomics.

Apr 27, 2021
1:40pm - 2:10pm (Eastern)
Expanding Precision Medicine into Chronic Disease - An opportunity to act on Type2 Diabetes Complications and Alzheimer's Disease

Dr. Gardner will present the challenge of moving Precision Medicine beyond oncology and rare disease, and how combinatorial analytics enables high resolution patient stratification enables us to accurately identify insights that enable us to understand disease biology in the context of patients.  We will exemplify how we are using the approach to develop combinatorial risk scores that predict diabetes complications at diagnosis and finding new insights into Alzhiemer’s disease biology that have clinical and pharmaceutical relevance.